{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T17:44:47Z","timestamp":1793123087737,"version":"4.5.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,30]],"date-time":"2021-01-30T00:00:00Z","timestamp":1611964800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,1,30]],"date-time":"2021-01-30T00:00:00Z","timestamp":1611964800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R03AI134222"],"award-info":[{"award-number":["R03AI134222"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Gene therapy approaches using hematopoietic stem cells to generate an HIV resistant immune system have been shown to be successful. The deletion of HIV co-receptor CCR5 remains a viable strategy although co-receptor switching to CXCR4 remains a major pitfall. To overcome this, we designed a dual gene therapy strategy that incorporates a conditional suicide gene and CCR5 knockout (KO) to overcome the limitations of CCR5 KO alone.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A two-vector system was designed that included an integrating lentiviral vector that expresses a HIV Tat dependent Thymidine Kinase mutant SR39 (TK-SR39) and GFP reporter gene. The second non-integrating lentiviral (NIL) vector expresses a CCR5gRNA-CRISPR\/Cas9 cassette and HIV Tat protein.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Transduction of cells sequentially with the integrating followed by the NIL vector allows for insertion of the conditional suicide gene, KO of CCR5 and transient expression of GFP to enrich the modified cells. We used this strategy to modify TZM cells and generate a cell line that was resistant to CCR5 tropic viruses while permitting infection of CXCR4 tropic viruses which could be controlled via treatment with Ganciclovir.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our study demonstrates proof of principle that a combination gene therapy for HIV is a viable strategy and can overcome the limitation of editing CCR5 gene alone.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12985-021-01501-7","type":"journal-article","created":{"date-parts":[[2021,1,30]],"date-time":"2021-01-30T13:02:52Z","timestamp":1612011772000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Combination gene therapy for HIV using a conditional suicidal gene with CCR5 knockout"],"prefix":"10.1186","volume":"18","author":[{"given":"Tugba","family":"Mehmetoglu-Gurbuz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rose","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Himanshu","family":"Garg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7979-3212","authenticated-orcid":false,"given":"Anjali","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,30]]},"reference":[{"key":"1501_CR1","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1100\/tsw.2011.102","volume":"11","author":"G Hutter","year":"2011","unstructured":"Hutter G, Ganepola S. Eradication of HIV by transplantation of CCR5-deficient hematopoietic stem cells. Sci World J. 2011;11:1068\u201376. https:\/\/doi.org\/10.1100\/tsw.2011.102.","journal-title":"Sci World J"},{"key":"1501_CR2","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1056\/NEJMoa0802905","volume":"360","author":"G Hutter","year":"2009","unstructured":"Hutter G, Nowak D, Mossner M, Ganepola S, Mussig A, Allers K, Schneider T, Hofmann J, Kucherer C, Blau O, et al. Long-term control of HIV by CCR5 Delta32\/Delta32 stem-cell transplantation. N Engl J Med. 2009;360:692\u20138. https:\/\/doi.org\/10.1056\/NEJMoa0802905.","journal-title":"N Engl J Med"},{"key":"1501_CR3","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1038\/s41586-019-1027-4","volume":"568","author":"RK Gupta","year":"2019","unstructured":"Gupta RK, Abdul-Jawad S, McCoy LE, Mok HP, Peppa D, Salgado M, Martinez-Picado J, Nijhuis M, Wensing AMJ, Lee H, et al. HIV-1 remission following CCR5Delta32\/Delta32 haematopoietic stem-cell transplantation. Nature. 2019;568:244\u20138. https:\/\/doi.org\/10.1038\/s41586-019-1027-4.","journal-title":"Nature"},{"key":"1501_CR4","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1056\/NEJMc1405805","volume":"371","author":"L Kordelas","year":"2014","unstructured":"Kordelas L, Verheyen J, Beelen DW, Horn PA, Heinold A, Kaiser R, Trenschel R, Schadendorf D, Dittmer U, Esser S. Shift of HIV tropism in stem-cell transplantation with CCR5 Delta32 mutation. N Engl J Med. 2014;371:880\u20132. https:\/\/doi.org\/10.1056\/NEJMc1405805.","journal-title":"N Engl J Med"},{"key":"1501_CR5","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2015.126","author":"H Garg","year":"2016","unstructured":"Garg H, Joshi A. Conditional cytotoxic anti-HIV gene therapy for selectable cell modification. Hum Gene Ther. 2016. https:\/\/doi.org\/10.1089\/hum.2015.126.","journal-title":"Hum Gene Ther"},{"key":"1501_CR6","doi-asserted-by":"publisher","first-page":"18088","DOI":"10.1038\/srep18088","volume":"5","author":"A Pandit","year":"2015","unstructured":"Pandit A, de Boer RJ. HIV-1 CCR5 gene therapy will fail unless it is combined with a suicide gene. Sci Rep. 2015;5:18088. https:\/\/doi.org\/10.1038\/srep18088.","journal-title":"Sci Rep"},{"key":"1501_CR7","doi-asserted-by":"publisher","first-page":"R23","DOI":"10.1093\/hmg\/ddn050","volume":"17","author":"L Chen","year":"2008","unstructured":"Chen L, Daley GQ. Molecular basis of pluripotency. Hum Mol Genet. 2008;17:R23-27. https:\/\/doi.org\/10.1093\/hmg\/ddn050.","journal-title":"Hum Mol Genet"},{"key":"1501_CR8","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/1743-422X-8-34","volume":"8","author":"H Garg","year":"2011","unstructured":"Garg H, Joshi A, Ye C, Shankar P, Manjunath N. Single amino acid change in gp41 region of HIV-1 alters bystander apoptosis and CD4 decline in humanized mice. Virol J. 2011;8:34. https:\/\/doi.org\/10.1186\/1743-422X-8-34.","journal-title":"Virol J"},{"key":"1501_CR9","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1016\/j.jcyt.2017.05.013","volume":"19","author":"KG Haworth","year":"2017","unstructured":"Haworth KG, Peterson CW, Kiem HP. CCR5-edited gene therapies for HIV cure: closing the door to viral entry. Cytotherapy. 2017;19:1325\u201338. https:\/\/doi.org\/10.1016\/j.jcyt.2017.05.013.","journal-title":"Cytotherapy"},{"key":"1501_CR10","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1742-4690-4-12","volume":"4","author":"Y Wu","year":"2007","unstructured":"Wu Y, Beddall MH, Marsh JW. Rev-dependent lentiviral expression vector. Retrovirology. 2007;4:12. https:\/\/doi.org\/10.1186\/1742-4690-4-12.","journal-title":"Retrovirology"},{"key":"1501_CR11","doi-asserted-by":"publisher","first-page":"12039","DOI":"10.1093\/nar\/gkx843","volume":"45","author":"G Yuen","year":"2017","unstructured":"Yuen G, Khan FJ, Gao S, Stommel JM, Batchelor E, Wu X, Luo J. CRISPR\/Cas9-mediated gene knockout is insensitive to target copy number but is dependent on guide RNA potency and Cas9\/sgRNA threshold expression level. Nucleic Acids Res. 2017;45:12039\u201353. https:\/\/doi.org\/10.1093\/nar\/gkx843.","journal-title":"Nucleic Acids Res"},{"key":"1501_CR12","doi-asserted-by":"publisher","first-page":"553","DOI":"10.2217\/rme.13.43","volume":"8","author":"G Pellegrini","year":"2013","unstructured":"Pellegrini G, Rama P, Matuska S, Lambiase A, Bonini S, Pocobelli A, Colabelli RG, Spadea L, Fasciani R, Balestrazzi E, et al. Biological parameters determining the clinical outcome of autologous cultures of limbal stem cells. Regen Med. 2013;8:553\u201367. https:\/\/doi.org\/10.2217\/rme.13.43.","journal-title":"Regen Med"},{"key":"1501_CR13","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1016\/S0140-6736(96)11188-0","volume":"349","author":"G Pellegrini","year":"1997","unstructured":"Pellegrini G, Traverso CE, Franzi AT, Zingirian M, Cancedda R, De Luca M. Long-term restoration of damaged corneal surfaces with autologous cultivated corneal epithelium. Lancet. 1997;349:990\u20133. https:\/\/doi.org\/10.1016\/S0140-6736(96)11188-0.","journal-title":"Lancet"},{"key":"1501_CR14","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1097\/00007890-200111150-00002","volume":"72","author":"P Rama","year":"2001","unstructured":"Rama P, Bonini S, Lambiase A, Golisano O, Paterna P, De Luca M, Pellegrini G. Autologous fibrin-cultured limbal stem cells permanently restore the corneal surface of patients with total limbal stem cell deficiency. Transplantation. 2001;72:1478\u201385. https:\/\/doi.org\/10.1097\/00007890-200111150-00002.","journal-title":"Transplantation"},{"key":"1501_CR15","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/s41556-019-0344-z","volume":"21","author":"M De Luca","year":"2019","unstructured":"De Luca M, Aiuti A, Cossu G, Parmar M, Pellegrini G, Robey PG. Advances in stem cell research and therapeutic development. Nat Cell Biol. 2019;21:801\u201311. https:\/\/doi.org\/10.1038\/s41556-019-0344-z.","journal-title":"Nat Cell Biol"},{"key":"1501_CR16","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan4672","author":"CE Dunbar","year":"2018","unstructured":"Dunbar CE, High KA, Joung JK, Kohn DB, Ozawa K, Sadelain M. Gene therapy comes of age. Science. 2018. https:\/\/doi.org\/10.1126\/science.aan4672.","journal-title":"Science"},{"key":"1501_CR17","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/nature15818","volume":"526","author":"L Naldini","year":"2015","unstructured":"Naldini L. Gene therapy returns to centre stage. Nature. 2015;526:351\u201360. https:\/\/doi.org\/10.1038\/nature15818.","journal-title":"Nature"},{"key":"1501_CR18","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1126\/science.273.5283.1856","volume":"273","author":"M Dean","year":"1996","unstructured":"Dean M, Carrington M, Winkler C, Huttley GA, Smith MW, Allikmets R, Goedert JJ, Buchbinder SP, Vittinghoff E, Gomperts E, et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia growth and development study, multicenter AIDS cohort study, multicenter hemophilia cohort study, San Francisco City Cohort, ALIVE study. Science. 1996;273:1856\u201362. https:\/\/doi.org\/10.1126\/science.273.5283.1856.","journal-title":"Science"},{"key":"1501_CR19","doi-asserted-by":"publisher","first-page":"237","DOI":"10.3390\/v9080237","volume":"9","author":"H Garg","year":"2017","unstructured":"Garg H, Joshi A. Host and viral factors in HIV-mediated bystander apoptosis. Viruses. 2017;9:237. https:\/\/doi.org\/10.3390\/v9080237.","journal-title":"Viruses"},{"key":"1501_CR20","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.virol.2016.03.010","volume":"493","author":"H Garg","year":"2016","unstructured":"Garg H, Lee RT, Maurer-Stroh S, Joshi A. HIV-1 adaptation to low levels of CCR5 results in V3 and V2 loop changes that increase envelope pathogenicity, CCR5 affinity and decrease susceptibility to Maraviroc. Virology. 2016;493:86\u201399. https:\/\/doi.org\/10.1016\/j.virol.2016.03.010.","journal-title":"Virology"},{"key":"1501_CR21","doi-asserted-by":"publisher","first-page":"3020","DOI":"10.3390\/v4113020","volume":"4","author":"H Garg","year":"2012","unstructured":"Garg H, Mohl J, Joshi A. HIV-1 induced bystander apoptosis. Viruses. 2012;4:3020\u201343. https:\/\/doi.org\/10.3390\/v4113020.","journal-title":"Viruses"},{"key":"1501_CR22","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.virol.2017.09.026","volume":"512","author":"A Joshi","year":"2017","unstructured":"Joshi A, Cox EK, Sedano MJ, Punke EB, Lee RT, Maurer-Stroh S, Kaur P, Ng OT, Garg H. HIV-1 subtype CRF01_AE and B differ in utilization of low levels of CCR5, Maraviroc susceptibility and potential N-glycosylation sites. Virology. 2017;512:222\u201333. https:\/\/doi.org\/10.1016\/j.virol.2017.09.026.","journal-title":"Virology"},{"key":"1501_CR23","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1074\/jbc.M113.514018","volume":"289","author":"A Joshi","year":"2014","unstructured":"Joshi A, Lee RT, Mohl J, Sedano M, Khong WX, Ng OT, Maurer-Stroh S, Garg H. Genetic signatures of HIV-1 envelope-mediated bystander apoptosis. J Biol Chem. 2014;289:2497\u2013514. https:\/\/doi.org\/10.1074\/jbc.M113.514018.","journal-title":"J Biol Chem"},{"key":"1501_CR24","doi-asserted-by":"publisher","first-page":"36404","DOI":"10.1074\/jbc.M111.281659","volume":"286","author":"A Joshi","year":"2011","unstructured":"Joshi A, Nyakeriga AM, Ravi R, Garg H. HIV ENV glycoprotein-mediated bystander apoptosis depends on expression of the CCR5 co-receptor at the cell surface and ENV fusogenic activity. J Biol Chem. 2011;286:36404\u201313. https:\/\/doi.org\/10.1074\/jbc.M111.281659.","journal-title":"J Biol Chem"},{"key":"1501_CR25","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/s41598-017-00192-x","volume":"7","author":"A Joshi","year":"2017","unstructured":"Joshi A, Punke EB, Sedano M, Beauchamp B, Patel R, Hossenlopp C, Alozie OK, Gupta J, Mukherjee D, Garg H. CCR5 promoter activity correlates with HIV disease progression by regulating CCR5 cell surface expression and CD4 T cell apoptosis. Sci Rep. 2017;7:232. https:\/\/doi.org\/10.1038\/s41598-017-00192-x.","journal-title":"Sci Rep"},{"issue":"1","key":"1501_CR26","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1186\/1479-5876-9-S1-S5","volume":"9","author":"H Schuitemaker","year":"2011","unstructured":"Schuitemaker H, van\u2019t Wout AB, Lusso P. Clinical significance of HIV-1 coreceptor usage. J Transl Med. 2011;9(1):S5. https:\/\/doi.org\/10.1186\/1479-5876-9-S1-S5.","journal-title":"J Transl Med"},{"key":"1501_CR27","doi-asserted-by":"publisher","first-page":"2940","DOI":"10.3389\/fmicb.2018.02940","volume":"9","author":"AG Allen","year":"2018","unstructured":"Allen AG, Chung CH, Atkins A, Dampier W, Khalili K, Nonnemacher MR, Wigdahl B. Gene EdiTing of HIV-1 co-receptors to prevent and\/or cure virus infection. Front Microbiol. 2018;9:2940. https:\/\/doi.org\/10.3389\/fmicb.2018.02940.","journal-title":"Front Microbiol"},{"key":"1501_CR28","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/gt.2015.101","volume":"23","author":"NY Petit","year":"2016","unstructured":"Petit NY, Baillou C, Burlion A, Dorgham K, Levacher B, Amiel C, Schneider V, Lemoine FM, Gorochov G, Marodon G. Gene transfer of two entry inhibitors protects CD4(+) T cell from HIV-1 infection in humanized mice. Gene Ther. 2016;23:144\u201350. https:\/\/doi.org\/10.1038\/gt.2015.101.","journal-title":"Gene Ther"},{"key":"1501_CR29","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1038\/nbt1367","volume":"25","author":"J Rossi","year":"2007","unstructured":"Rossi J, June C, Kohn D. Genetic therapies against HIV. Nat Biotechnol. 2007;25:1444\u201354.","journal-title":"Nat Biotechnol"},{"key":"1501_CR30","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1089\/hum.2015.059","volume":"26","author":"U Jung","year":"2015","unstructured":"Jung U, Urak K, Veillette M, Nepveu-Traversy ME, Pham QT, Hamel S, Rossi JJ, Berthoux L. Preclinical assessment of mutant human TRIM5alpha as an Anti-HIV-1 transgene. Hum Gene Ther. 2015;26:664\u201379. https:\/\/doi.org\/10.1089\/hum.2015.059.","journal-title":"Hum Gene Ther"},{"key":"1501_CR31","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/978-1-4939-2432-5_4","volume":"848","author":"E Herrera-Carrillo","year":"2015","unstructured":"Herrera-Carrillo E, Berkhout B. Gene therapy strategies to block HIV-1 replication by RNA interference. Adv Exp Med Biol. 2015;848:71\u201395. https:\/\/doi.org\/10.1007\/978-1-4939-2432-5_4.","journal-title":"Adv Exp Med Biol"},{"key":"1501_CR32","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nature10660","volume":"481","author":"AB Balazs","year":"2011","unstructured":"Balazs AB, Chen J, Hong CM, Rao DS, Yang L, Baltimore D. Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature. 2011;481:81\u20134. https:\/\/doi.org\/10.1038\/nature10660.","journal-title":"Nature"},{"key":"1501_CR33","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1038\/nm.1967","volume":"15","author":"PR Johnson","year":"2009","unstructured":"Johnson PR, Schnepp BC, Zhang J, Connell MJ, Greene SM, Yuste E, Desrosiers RC, Clark KR. Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys. Nat Med. 2009;15:901\u20136. https:\/\/doi.org\/10.1038\/nm.1967.","journal-title":"Nat Med"},{"key":"1501_CR34","doi-asserted-by":"publisher","first-page":"8334","DOI":"10.1128\/JVI.00908-15","volume":"89","author":"KO Saunders","year":"2015","unstructured":"Saunders KO, Wang L, Joyce MG, Yang ZY, Balazs AB, Cheng C, Ko SY, Kong WP, Rudicell RS, Georgiev IS, et al. Broadly neutralizing human immunodeficiency virus type 1 antibody gene transfer protects nonhuman primates from mucosal simian-human immunodeficiency virus infection. J Virol. 2015;89:8334\u201345. https:\/\/doi.org\/10.1128\/JVI.00908-15.","journal-title":"J Virol"},{"key":"1501_CR35","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1038\/mt.2015.70","volume":"23","author":"RS Leibman","year":"2015","unstructured":"Leibman RS, Riley JL. Engineering T cells to functionally cure HIV-1 infection. Mol Ther. 2015;23:1149\u201359. https:\/\/doi.org\/10.1038\/mt.2015.70.","journal-title":"Mol Ther"},{"key":"1501_CR36","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1172\/JCI46110","volume":"121","author":"B Savoldo","year":"2011","unstructured":"Savoldo B, Ramos CA, Liu E, Mims MP, Keating MJ, Carrum G, Kamble RT, Bollard CM, Gee AP, Mei Z, et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Investig. 2011;121:1822\u20136. https:\/\/doi.org\/10.1172\/JCI46110.","journal-title":"J Clin Investig"},{"key":"1501_CR37","doi-asserted-by":"publisher","first-page":"9870","DOI":"10.1073\/pnas.89.20.9870","volume":"89","author":"D Bevec","year":"1992","unstructured":"Bevec D, Dobrovnik M, Hauber J, Bohnlein E. Inhibition of human immunodeficiency virus type 1 replication in human T cells by retroviral-mediated gene transfer of a dominant-negative Rev trans-activator. Proc Natl Acad Sci USA. 1992;89:9870\u20134. https:\/\/doi.org\/10.1073\/pnas.89.20.9870.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1501_CR38","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/0092-8674(89)90874-x","volume":"59","author":"D Trono","year":"1989","unstructured":"Trono D, Feinberg MB, Baltimore D. HIV-1 Gag mutants can dominantly interfere with the replication of the wild-type virus. Cell. 1989;59:113\u201320. https:\/\/doi.org\/10.1016\/0092-8674(89)90874-x.","journal-title":"Cell"},{"key":"1501_CR39","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1006\/viro.2001.0944S0042-6822(01)90944-4[pii]","volume":"286","author":"Y Iwatani","year":"2001","unstructured":"Iwatani Y, Kawano K, Ueno T, Tanaka M, Ishimoto A, Ito M, Sakai H. Analysis of dominant-negative effects of mutant Env proteins of human immunodeficiency virus type 1. Virology. 2001;286:45\u201353. https:\/\/doi.org\/10.1006\/viro.2001.0944S0042-6822(01)90944-4[pii].","journal-title":"Virology"},{"key":"1501_CR40","doi-asserted-by":"publisher","first-page":"14365","DOI":"10.1073\/pnas.0804461105","volume":"105","author":"M Legiewicz","year":"2008","unstructured":"Legiewicz M, Badorrek CS, Turner KB, Fabris D, Hamm TE, Rekosh D, Hammarskjold ML, Le Grice SF. Resistance to RevM10 inhibition reflects a conformational switch in the HIV-1 Rev response element. Proc Natl Acad Sci USA. 2008;105:14365\u201370. https:\/\/doi.org\/10.1073\/pnas.0804461105.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1501_CR41","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.virol.2011.03.028","volume":"415","author":"A Joshi","year":"2011","unstructured":"Joshi A, Garg H, Ablan S, Freed EO, Nagashima K, Manjunath N, Shankar P. Targeting the HIV entry, assembly and release pathways for anti-HIV gene therapy. Virology. 2011;415:95\u2013106. https:\/\/doi.org\/10.1016\/j.virol.2011.03.028.","journal-title":"Virology"},{"key":"1501_CR42","doi-asserted-by":"publisher","first-page":"307","DOI":"10.2174\/1566523023347733","volume":"2","author":"IJ van Dillen","year":"2002","unstructured":"van Dillen IJ, Mulder NH, Vaalburg W, de Vries EF, Hospers GA. Influence of the bystander effect on HSV-tk\/GCV gene therapy. A review Curr Gene Ther. 2002;2:307\u201322. https:\/\/doi.org\/10.2174\/1566523023347733.","journal-title":"A review Curr Gene Ther"},{"key":"1501_CR43","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.14916","author":"FV Jacinto","year":"2020","unstructured":"Jacinto FV, Link W, Ferreira BI. CRISPR\/Cas9-mediated genome editing: from basic research to translational medicine. J Cell Mol Med. 2020. https:\/\/doi.org\/10.1111\/jcmm.14916.","journal-title":"J Cell Mol Med"},{"key":"1501_CR44","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/j.tibtech.2019.01.009","volume":"37","author":"SB Moon","year":"2019","unstructured":"Moon SB, Kim DY, Ko JH, Kim JS, Kim YS. Improving CRISPR genome editing by engineering guide RNAs. Trends Biotechnol. 2019;37:870\u201381. https:\/\/doi.org\/10.1016\/j.tibtech.2019.01.009.","journal-title":"Trends Biotechnol"},{"key":"1501_CR45","doi-asserted-by":"publisher","first-page":"R79","DOI":"10.1093\/hmg\/ddy120","volume":"27","author":"C Zhang","year":"2018","unstructured":"Zhang C, Quan R, Wang J. Development and application of CRISPR\/Cas9 technologies in genomic editing. Hum Mol Genet. 2018;27:R79\u201388. https:\/\/doi.org\/10.1093\/hmg\/ddy120.","journal-title":"Hum Mol Genet"},{"key":"1501_CR46","doi-asserted-by":"publisher","first-page":"e0188593","DOI":"10.1371\/journal.pone.0188593","volume":"12","author":"M Basila","year":"2017","unstructured":"Basila M, Kelley ML, Smith AVB. Minimal 2\u2019-O-methyl phosphorothioate linkage modification pattern of synthetic guide RNAs for increased stability and efficient CRISPR-Cas9 gene editing avoiding cellular toxicity. PLoS ONE. 2017;12:e0188593. https:\/\/doi.org\/10.1371\/journal.pone.0188593.","journal-title":"PLoS ONE"},{"key":"1501_CR47","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/nbt.3290","volume":"33","author":"A Hendel","year":"2015","unstructured":"Hendel A, Bak RO, Clark JT, Kennedy AB, Ryan DE, Roy S, Steinfeld I, Lunstad BD, Kaiser RJ, Wilkens AB, et al. Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells. Nat Biotechnol. 2015;33:985\u20139. https:\/\/doi.org\/10.1038\/nbt.3290.","journal-title":"Nat Biotechnol"},{"key":"1501_CR48","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1038\/nbt.4005","volume":"35","author":"H Yin","year":"2017","unstructured":"Yin H, Song CQ, Suresh S, Wu Q, Walsh S, Rhym LH, Mintzer E, Bolukbasi MF, Zhu LJ, Kauffman K, et al. Structure-guided chemical modification of guide RNA enables potent non-viral in vivo genome editing. Nat Biotechnol. 2017;35:1179\u201387. https:\/\/doi.org\/10.1038\/nbt.4005.","journal-title":"Nat Biotechnol"},{"key":"1501_CR49","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.25312","author":"K Lee","year":"2017","unstructured":"Lee K, Mackley VA, Rao A, Chong AT, Dewitt MA, Corn JE, Murthy N. Synthetically modified guide RNA and donor DNA are a versatile platform for CRISPR-Cas9 engineering. Elife. 2017. https:\/\/doi.org\/10.7554\/eLife.25312.","journal-title":"Elife"},{"key":"1501_CR50","first-page":"846","volume":"39","author":"M Reisman","year":"2014","unstructured":"Reisman M, Adams KT. Stem cell therapy: a look at current research, regulations, and remaining hurdles. P T. 2014;39:846\u201357.","journal-title":"P T"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-021-01501-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12985-021-01501-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-021-01501-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,30]],"date-time":"2021-01-30T13:08:33Z","timestamp":1612012113000},"score":1,"resource":{"primary":{"URL":"https:\/\/virologyj.biomedcentral.com\/articles\/10.1186\/s12985-021-01501-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,30]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1501"],"URL":"https:\/\/doi.org\/10.1186\/s12985-021-01501-7","relation":{},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,30]]},"assertion":[{"value":"18 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"31"}}